Harrow Launches Direct-to-Prescriber Cash-Pay Kits for Ophthalmic Surgery
Event summary
- Harrow launched PharmaPack, a direct-to-prescriber cash-pay offering for ophthalmic surgery products, initially available in five U.S. states.
- PharmaPack kits include FDA-approved products like NEVANAC, TOBRADEX ST, and MAXITROL, targeting infection control and post-surgery pain management.
- The program aims to reduce administrative complexity and regulatory risks associated with off-label compounded products.
- Harrow plans nationwide expansion of PharmaPack in the coming weeks.
The big picture
Harrow's PharmaPack launch targets a growing demand for affordable, FDA-approved ophthalmic products, addressing administrative and regulatory challenges in the ophthalmology sector. The direct-to-prescriber model could disrupt traditional insurance-dependent distribution channels, potentially reshaping the market dynamics for post-surgery care products. The initial rollout in select states, with plans for nationwide expansion, signals Harrow's strategic push to capture a larger share of the ophthalmic surgery market.
What we're watching
- Market Adoption
- How quickly prescribers will adopt PharmaPack kits in place of traditional insurance-covered or compounded products.
- Regulatory Compliance
- Whether the cash-pay model will face regulatory scrutiny or pushback from insurers.
- Competitive Response
- The pace at which competitors will introduce similar direct-to-prescriber offerings.
Related topics